Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
heart failure
Biotech
AstraZeneca's heart failure drug shows promise in ph. 2 trial
In moderate-to-severe heart failure, the lowest dose of AZD5462 decreased end-systolic volume index by 5.4 mL/m2.
Marissa Russo
Aug 31, 2026 11:13am
AstraZeneca relaxed about relaxin drug's poor efficacy in ph. 2
Feb 10, 2026 7:50am
NICE greenlights Abbott's cardiac sensor implant for NHS
Feb 6, 2026 5:45am
Impulse Dynamics clinches $158M for heart failure implant
Dec 12, 2025 11:10am
FDA panel votes against J&J shunt implant for heart failure
Dec 5, 2025 4:31pm
Cytokinetics doesn't want Big Pharma help to overtake Camzyos
Nov 18, 2025 1:30pm
